Myocardial Fibrosis - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Myocardial Fibrosis - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Myocardial Fibrosis - Pipeline Review, H2 2015', provides an overview of the Myocardial Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Myocardial Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Myocardial Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myocardial Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Fibrosis Overview 7
Therapeutics Development 8
Pipeline Products for Myocardial Fibrosis - Overview 8
Pipeline Products for Myocardial Fibrosis - Comparative Analysis 9
Myocardial Fibrosis - Therapeutics under Development by Companies 10
Myocardial Fibrosis - Therapeutics under Investigation by Universities/Institutes 11
Myocardial Fibrosis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Myocardial Fibrosis - Products under Development by Companies 14
Myocardial Fibrosis - Products under Investigation by Universities/Institutes 15
Myocardial Fibrosis - Companies Involved in Therapeutics Development 16
AstraZeneca Plc 16
BioLineRx, Ltd. 17
Digna Biotech, S.L. 18
Evotec AG 19
Galectin Therapeutics, Inc. 20
GTx, Inc. 21
MandalMed, Inc. 22
miRagen Therapeutics, Inc. 23
ProMetic Life Sciences Inc. 24
Virocan Therapeutics Private Limited 25
Myocardial Fibrosis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
AmVicf-006 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
AZ-876 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CGEN-856 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
disitertide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs for Tissue Fibrosis - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Galectin-3C - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
GM-CT-01 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
GRMD-02 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GTx-878 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
MGN-4220 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
P-17 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PBI-4050 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule for Cardiac Fibrosis and Heart Failure - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SP-20102 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
TM-5441 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Myocardial Fibrosis - Recent Pipeline Updates 59
Myocardial Fibrosis - Dormant Projects 73
Myocardial Fibrosis - Product Development Milestones 74
Featured News & Press Releases 74
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 74
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Myocardial Fibrosis, H2 2015 8
Number of Products under Development for Myocardial Fibrosis - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Myocardial Fibrosis - Pipeline by AstraZeneca Plc, H2 2015 16
Myocardial Fibrosis - Pipeline by BioLineRx, Ltd., H2 2015 17
Myocardial Fibrosis - Pipeline by Digna Biotech, S.L., H2 2015 18
Myocardial Fibrosis - Pipeline by Evotec AG, H2 2015 19
Myocardial Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2015 20
Myocardial Fibrosis - Pipeline by GTx, Inc., H2 2015 21
Myocardial Fibrosis - Pipeline by MandalMed, Inc., H2 2015 22
Myocardial Fibrosis - Pipeline by miRagen Therapeutics, Inc., H2 2015 23
Myocardial Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2015 24
Myocardial Fibrosis - Pipeline by Virocan Therapeutics Private Limited, H2 2015 25
Assessment by Monotherapy Products, H2 2015 26
Number of Products by Stage and Target, H2 2015 28
Number of Products by Stage and Mechanism of Action, H2 2015 30
Number of Products by Stage and Route of Administration, H2 2015 32
Number of Products by Stage and Molecule Type, H2 2015 34
Myocardial Fibrosis Therapeutics - Recent Pipeline Updates, H2 2015 59
Myocardial Fibrosis - Dormant Projects, H2 2015 73